HCC surveillance results in earlier HCC detection: results from an Indian cohort by Anita Kohli et al.
a SpringerOpen Journal
Kohli et al. SpringerPlus 2014, 3:610
http://www.springerplus.com/content/3/1/610RESEARCH Open AccessHCC surveillance results in earlier HCC detection:
results from an Indian cohort
Anita Kohli1,5†, Allison A Murphy1†, Chirdeep Agarwal2, Bhavana Shivakumar1, Shyam Kottilil1, Michael A Polis1,
G Mani Subramanian6, Vandana Midha3, Omesh Goyal3, Srinivas Desai4, Ajit Sood3 and Samir Shah2*Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide, with an
increased incidence in South Asia. In order to describe the effect of surveillance for HCC with biannual ultrasound
and alpha-fetoprotein (AFP) on diagnosis and survival in an Indian population a retrospective cohort-control study was
performed at two liver clinics in India. The medical records of 3,258 patients with cirrhosis who received surveillance for
HCC were reviewed, and 100 patients who developed HCC identified. Sixty-four cirrhotic patients diagnosed with HCC
during the same time period without a history of surveillance were included and survival, BCLC stage at diagnosis, and
treatment were compared.
Patients who underwent surveillance were more likely to be diagnosed with potentially curable or treatable BCLC
Stage 0/A disease and Stage B/C disease respectively, than late Stage D disease (χ2 = 0.0007). Patients diagnosed
at an earlier stage of HCC lived significantly longer after diagnosis than patients diagnosed at a later stage (Stage
0/A: 15.6 ± 14.2 months vs. Stage B/C: 9.43 ± 19.7 months vs. Stage D: 5.59 ± 11.9 months; p = 0.0006). While
treatment for HCC improved overall survival, only 28% of eligible patients received treatment, explaining the lack of
survival benefit noted in the surveillance group. Surveillance for HCC led to detection of HCC at earlier stages. The
impact of surveillance on improved mortality could not be evaluated given the limited number of patients who
received treatment. HCC surveillance has the potential to improve survival in South Asian patients with cirrhosis only
if improvements in access to appropriate treatment are made.
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Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer-related death worldwide, with an
increased incidence in South East Asia. In India there
are 19,000 new cases of HCC and 17,000 deaths due to
HCC annually (Ferlay et al. 2010). Given the prevalence
of two major risk factors for HCC in India, chronic
hepatitis C (HCV) (1–1.9% population) (Sievert et al.
2011) and active hepatitis B (HBV) (~2.4%) (Batham et al.
2007), in combination with an aging population of patients
expected to develop advanced liver disease, the incidence
of HCC in India can be expected to increase.
Overall, prognosis after diagnosis of HCC is dependent
on the stage of disease as well as the availability of* Correspondence: drshahsamir@gmail.com
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in any medium, provided the original work is pappropriate individualized treatment modalities (Forner
et al. 2010). In this regard, strategies for detection HCC
at an early stage have been evaluated. Surveillance of
high-risk patients with hepatitis and/or cirrhosis using
biannual ultrasound and serum AFP testing has been
shown to enable earlier detection of malignant tumor
and prolong survival (Zhang et al. 2004) in a Chinese
population, as well as to be a cost effective strategy in a
US population (Bruix and Sherman 2011).
Limited retrospective studies on the epidemiology of
HCC in India have been performed, most of which
report that patients initial presentation is at an advanced
stage of HCC disease (Kumar et al. 2008). In this study,
we investigated the impact of existing standard HCC
surveillance procedures on survival in two distinct
geographic regions in India.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Demographics of patients diagnosed with HCC





Age- mean ± SD (years) 58 ± 9.6 59 ± 10.5 p = 0.70
AFP- mean ± SD (ng/mL) 2424 ± 9475 10275 ± 63429 p = 0.33
Size of lesions- mean
± SD (cm)
5.00 ± 2.71 5.73 ± 3.42 p = 0.23
Gender- male n (%) 85 (85%) 52 (81%) χ2=0.53
Child-pugh class
A 22 (22%) 10 (16%)
χ2=0.04B 36 (36%) 36 (56%)




HBV only 7 (7%) 3 (5%)
HBV & ETOH 1 (1%) 0 (0%)
HCV
HCV only 23 (23%) 19 (30%)
HCV & ETOH 17 (17%) 14 (22%)
ETOH only 26 (26%) 9 (14%)
HBV & HCV & ETOH 23 (23%) 17 (27%)
Unknown 3 (3%) 2 (3%)
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A retrospective cohort-control study was performed at
two specialty liver clinics in Mumbai, Maharashtra
(western India) and Ludhiana, Punjab (northern India).
The medical records of 3,258 patients with cirrhosis due
to HBV, HCV or alcohol use who received surveillance
for HCC for a minimum of 12 months were reviewed.
Surveillance consisted of an abdominal ultrasound
examination and serum alpha-fetoprotein testing every
6 months for at least 12 months. All ultrasounds were
performed by trained radiologists. One hundred patients
who developed HCC between July 1999 and Aug 2012
were identified for inclusion. An additional 64 cirrhotic
patients from Mumbai without a history of surveil-
lance, who at first presentation were diagnosed with
HCC during the same time period, were included for
comparison. Patients who received treatment for HCC
were, in most cases, treated with therapeutic strategies
consistent with the Barcelona Clinic Liver Cancer
(BCLC) system (Bruix and Llovett 2002). Combination
therapy was used when clinically indicated. For patients
who received sequential therapy, the first therapy re-
ceived is reported. Baseline demographics including
risk factors for HCC (history of alcohol abuse (ETOH),
HBV status and HCV status), BCLC stage at diagnosis,
treatment received, and survival were recorded using a
standardized questionnaire.
Informed consent was obtained from patients where
appropriate. The IRB of the National Institutes of
Allergy and Infectious Disease, NIH, Bethesda, MD
approved this study and all investigations have been
carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2000.
Statistical analysis
Statistical analyses were performed using SAS Version
9.2 and Prism version 5.0. Categorical values were
compared using the Pearson Chi-square test. Two-
tailed Student’s T-tests were used to compare means. A
p-value of <0.05 was considered significant. Kaplan-Meier




Patient demographics are shown in Table 1. The
majority of patients were men (83.5%). There was no
significant difference in the age, gender, stage of liver
disease at HCC diagnosis or risk factors for HCC
between patients who received surveillance as com-
pared to those who did not receive surveillance.
Patients who underwent surveillance were more likely
to present with Child-Pugh C disease than patients
who did not receive surveillance. AFP was elevated(>20 ng/mL) in 76.8% of patients at the time of HCC
diagnosis, with no difference between patients who
did or did not undergo surveillance (p = 0.15).
Surveillance result in earlier detection of HCC
Patients with cirrhosis who underwent HCC surveillance
were more likely to be diagnosed with HCC that was
either potentially curable (BCLC Stage 0/A) or with
HCC eligible for treatment with life-prolonging therapies
(Stage B/C disease) than patients who did not undergo
surveillance (Stage 0/A: 11% surveillance vs. 7% no sur-
veillance; Stage B/C 66% surveillance vs. 42% no surveil-
lance; Stage D 23% surveillance vs. 51% no surveillance
vs.; χ2 = 0.0007) (Table 2).
Surveillance improves overall survival in patients with
access to appropriate HCC treatment
Patients diagnosed at an earlier stage of HCC lived
significantly longer after diagnosis than patients diag-
nosed at a later stage (Stage 0/A: 15.6 ± 14.2 months vs.
Stage B/C: 9.43 ± 19.7 months vs. Stage D: 5.59 ±
11.9 months; p = 0.0006) (Figure 1A). Despite the find-
ing that surveillance led to diagnosis of HCC at earlier
stages, we did not find a difference in the overall
survival of patients who did and did not undergo
routine surveillance (p = 0.48) (Figure 1B).
Table 2 Patients undergoing surveillance diagnosed with





BCLC stage at diagnosis
0/A 11 (11%) 4 (7%)
χ2=0.0007B/C 66 (66%) 27 (42%)
D 23 (23%) 33 (51%)
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disease at the time of diagnosis received treatment for
HCC treatment. Patients with stage 0/A disease were
more likely to receive treatment than patients diagnosed
with stage B/C or stage D HCC (53.3% of Stage 0/A
disease treated, 22.0% of Stage B/C disease treated and
10.2% of Stage D treated, χ2 = 0.0016). Among patients
who were treated, the most common treatment modal-
ities are shown in Table 3. There was no difference in
treatment modalities used in patients who did or did not
undergo surveillance (χ2 < 0.05).
Patients who received potentially curative treatment
for Stage 0 or A disease (Figure 2A) or life-prolonging
therapy for Stage B or C disease (Figure 2B) survived
longer as compared patients of the same stage who did
not receive treatment (Stage 0/A: 20.3 ± 25.9 months
treated vs. 11.0 ± 5.4 months untreated, p = 0.3817; Stage
B/C: 33.0 ± 34.9 months treated vs. 4.8 ± 8.2 months
untreated, p < 0.0001). However, this difference was
significant only for patients with Stage B/C disease.
Using a logistic regression model including age, gender
and stage of HCC and Child-Pugh score, only Child-
Pugh Scores at diagnosis was a risk factor for not receiv-
ing treatment (p = 0.0005).
Discussion
In this study, we demonstrate that systematic surveil-
lance for HCC in cirrhotic patients leads to earlierFigure 1 Impact of disease stage and surveillance on survival. A. Impr
earlier stage of HCC lived significantly longer after diagnosis than patients
9.43 ± 19.7 months vs. Stage D: 5.59 ± 11.9 months; p = 0.0006). B. Surveillan
surveillance led to increased diagnosis of early stage HCC, we did not find
undergo routine surveillance (p > 0.05).diagnosis of HCC in India. In addition early diagnosis
and appropriate therapy for HCC did prolong survival.
We did not find that surveillance improved overall sur-
vival, however treatment for HCC after diagnosis was
uncommon in this cohort limiting the ability to make
conclusions about the impact of surveillance on survival.
Findings in this study support the efficacy of biannual
U/S and AFP testing as an HCC surveillance strategy to
detect early stage disease in a South Asian population.
Efforts to understand barriers to the receipt of treatment
for HCC will be important in order to improve mortality
in Indian patients with HCC.
HCC is a large and increasing problem in India given
the high prevalence of risk factors, including viral hepa-
titis, in the general population. Infection with viral hepa-
titis (HBV and/or HCV) as a risk factor for HCC in our
cohorts reflected the distribution of viral hepatitis in
India, with about half of the cases related to HBV and
half of the cases related to HCV. Men were predomin-
antly affected by HCC, again, reflecting the epidemiology
of risk factors for cirrhosis (El-Serag 2012). The majority
of patients in this study had a history of excessive alco-
hol use and one quarter of patients had alcohol as their
only risk factor for HCC, suggesting barriers to further
medical treatment in this traditionally difficult-to-retain
patient population. Diagnostic level of serum AFP was
seen in many but not all patients at the time of HCC
diagnosis, similar to other reports describing the pre-
sentation of HCC in India (Kumar et al. 2008), and
highlighting the limited utility of this assay alone as a
screening tool (Oka et al. 1994).
Given the poor prognosis and insidious onset of late
stage HCC, efforts to develop effective surveillance
measures to detect disease at an early stage in high-risk
patients, when curative or life-prolonging therapies are
more effective, are ongoing. Biannual screening using
ultrasound with or without AFP as done in this study is
the gold standard for the screening of HCC with a sensi-
tivity of 57-100% (Snowberger et al. 2007; Singal et al.oved Survival After Early Diagnosis of HCC. Patients diagnosed at an
diagnosed at a later stage (Stage 0/A: 15.6 ± 14.2 months vs. Stage B/C:
ce for HCC Does Not Improve Survival. Despite the finding that
a difference in the overall survival of patients who did and did not
Table 3 Treatment of Hepatocellular Carcinoma in India
















0 1 (5.00%) 0 0 0 0 0 1 (50.0%) 0
A 6 (46.0%) 3 (21.4%) 1 (7.7%) 0 1 (7.7%) 0 2 (14.3%) 0
B 36 (69.2%) 5 (9.6%) 5 (9.6%) 2 (3.9%) 0 0 2 (3.9%) 2 (3.9%)
C 29 (87.9%) 1 (3.0%) 0 2 (6.1%) 0 1 (3.0%) 0 0
D 53 (88.3%) 1 (1.7%) 0 0 3 (5.0%) 0 0 2 (3.3%)
RFA Radiofrequency Frequency Ablation.
TACE Transarterial Chemoembolization.
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37% reduction in mortality despite a relatively low com-
pliance rate with screening of 60% (Zhang et al. 2004).
Overall however, these data reiterate the need for novel
biomarkers that can detect HCC at earlier time point
than present surveillance strategies, which require fre-
quent visits and have variable sensitivity.
In our cohort, most patients presented with an
advanced stage of HCC, similar to other Indian cohorts
(Kumar et al. 2008). We, however, were able to detect
stage-migration, which is the ability of biannual ultra-
sound and AFP surveillance to detect disease at an
earlier stage as compared to patients who did not
undergo surveillance. Surveillance tools however, are
effective at reducing mortality only when diagnosed
patients are linked to effective, life-prolonging treat-
ments (Di Bisceglie 2004). We did not find a direct effect
of surveillance on mortality reduction. This is likely due
to the low proportion of patients who received treatment
for HCC. Survival however, was prolonged for treated
patients compared to those who did not receive treat-
ment, with success rates comparable to those reported
in other studies (de Lope et al. 2012; Cillo et al. 2006).
This suggests that routine surveillance to diagnose
patients with early curable or treatable disease coupledFigure 2 Impact of Treatment for HCC on Survival. A. Survival in Treate
the small number of patients with Stage 0/A HCC was similar between trea
for untreated patients; p = 0.3817). B. Treatment Improves Survival Patients
or C disease survived longer as compared patients of the same stage who did
untreated; p < 0.0001).with linkage to appropriate therapy could improve mor-
tality due to HCC in this Indian population.
Access to appropriate treatment HCC in India is fre-
quently impeded by barriers. In particular, living donor or
cadaveric liver transplantation, an important and potentially
curative therapeutic strategy, is rare in India, with only two
active transplant centers performing about 1,000 trans-
plants per year. Larger studies to determine the efficacy of
current screening strategies as well as to understand and
mitigate barriers to care for patients in India (cost, access
to transplant centers, alcohol use) with HCC are critical.
Limitations of this study include retrospective design,
retrospective classification of HCC disease and BCLC
staging criteria and small numbers of treated patients
with HCC, thereby restricting the ability of this study to
detect survival advantages in the surveillance or non-
surveillance groups.
Our study emphasizes three important points. First,
vigilant surveillance strategies for HCC in patients who
have cirrhosis is vital for early detection. Second, in order
to improve the extremely low overall survival rates
observed even in the surveillance group, better access/link-
age to care with early individualized therapeutic modalities
are absolutely necessary to have an impact on the overall
morbidity and mortality associated with HCC in India.d Patients with BCLC Stage 0/A Hepatocellular Carcinoma. Survival in
ted and untreated patients (20.3 ± 25.9 months vs. 11.0 ± 5.4 months
with BCLC Stage B/C Hepatocellular Carcinoma. Patients with Stage B
not receive treatment (33.0 ± 34.9 months treated vs. 4.8 ± 8.2 months
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